- Home
- GALT
GALT
Galectin Therapeutics Inc.
as 07-26-2024 4:00pm EST
| Founded: | 2000 | Country: | United States |
| Employees: | N/A | City: | NORCROSS |
| Market Cap: | N/A | IPO Year: | N/A |
| Target Price: | $11.00 | AVG Volume (30 days): | 270.1K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 1 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.74 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.35 - $4.27 | Next Earning Date: | 08-12-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of Galectin Therapeutics Inc. (GALT)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| ELDRED KARY | GALT | Director | Jul 22 '24 | Buy | $2.39 | 400 | $956.00 | 49,713 | SEC Form 4 |
| FREEMAN KEVIN D | GALT | Director | Jun 20 '24 | Buy | $2.38 | 2,500 | $5,949.75 | 28,469 | SEC Form 4 |
| Zordani Richard A. Jr. | GALT | Director | Apr 30 '24 | Buy | $3.52 | 1,000 | $3,520.00 | 1,000 | SEC Form 4 |
| LEWIS JOEL | GALT | President and CEO | Apr 24 '24 | Buy | $3.39 | 1,000 | $3,390.00 | 2,000 | SEC Form 4 |
| CZIRR JAMES C | GALT | 10% Owner | Apr 22 '24 | Sell | $3.06 | 3,677 | $11,251.62 | 5,922,207 | SEC Form 4 |
| CZIRR JAMES C | GALT | 10% Owner | Apr 22 '24 | Sell | $3.06 | 21,323 | $65,248.38 | 5,925,884 | SEC Form 4 |
| FREEMAN KEVIN D | GALT | Director | Apr 22 '24 | Buy | $2.98 | 2,500 | $7,450.00 | 25,969 | SEC Form 4 |
| ELDRED KARY | GALT | Director | Jan 16 '24 | Buy | $1.79 | 500 | $892.90 | 49,313 | SEC Form 4 |
Latest Galectin Therapeutics Inc. News
GALT Breaking Stock News: Dive into GALT Ticker-Specific Updates for Smart Investing
Investor's Business Daily
2 months ago
IBD Stock Of The Day Meta Rolls Out New AI Tools For Businesses
Business Wire
2 months ago
Credo AI Launches the World's Largest and Most Comprehensive AI Risk and Controls Library
Investor's Business Daily
2 months ago
Dow Jones Futures: Apple AI Launch, Tesla Shareholder Meeting, Fed Rate 'Dot Plot' On Tap
GlobeNewswire
2 months ago
EnviroGold Global Closes First Tranche of Private Placement
GuruFocus.com
2 months ago
Insider Sale: Director Carol Lowe Sells Shares of EMCOR Group Inc (EME)
Yahoo Finance Video
2 months ago
How markets digested hot jobs print: Top takeaways
PR Newswire
2 months ago
SoCalGas Volunteers to Help Sort 1.8 Million Pounds of Food to Help Labor Community Services "Stamp Out Hunger"
GlobeNewswire
2 months ago
Nova Leap Health Corp. Announces Results of Annual and Special Meeting of Shareholders
Compare GALT vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "GALT Galectin Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.